Personalis, Inc. (NASDAQ:PSNL) Stock Position Increased by Barclays PLC

Barclays PLC boosted its position in shares of Personalis, Inc. (NASDAQ:PSNL) by 45.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 65,468 shares of the company’s stock after buying an additional 20,444 shares during the quarter. Barclays PLC owned 0.09% of Personalis worth $352,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of PSNL. nVerses Capital LLC bought a new position in shares of Personalis during the 3rd quarter valued at about $40,000. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its holdings in Personalis by 42.5% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock worth $81,000 after buying an additional 4,504 shares in the last quarter. International Assets Investment Management LLC grew its position in Personalis by 438.0% in the third quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock worth $113,000 after buying an additional 17,082 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Personalis in the third quarter valued at $210,000. Finally, Semanteon Capital Management LP acquired a new stake in shares of Personalis during the 3rd quarter valued at $375,000. 61.91% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PSNL has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Personalis in a report on Wednesday, January 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $7.25 price objective on shares of Personalis in a research note on Wednesday, January 8th. Finally, Lake Street Capital lifted their target price on shares of Personalis from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th.

Personalis Stock Performance

PSNL stock opened at $4.89 on Monday. The firm has a 50 day simple moving average of $4.72 and a 200 day simple moving average of $4.54. Personalis, Inc. has a 52 week low of $1.12 and a 52 week high of $7.20. The stock has a market cap of $345.48 million, a P/E ratio of -2.91 and a beta of 1.75.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.31). Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The firm had revenue of $25.71 million for the quarter, compared to analysts’ expectations of $20.67 million. During the same quarter in the prior year, the business posted ($0.51) earnings per share. Sell-side analysts predict that Personalis, Inc. will post -1.37 EPS for the current year.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.